Strides Board approves incremental investments in Stelis
It will accelerate Strides’ re-entry into sterile injectables business post the completion of the Company’s non-compete period in December 2019
Strides Pharma announced that the Board of Directors of the Company have approved an additional investment up to US$ 40 million over a period of 24 months for a controlling stake in Stelis Biopharma.
The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space.
It will also accelerate Strides’ re-entry into sterile injectables business post the completion of the Company’s non-compete period in December 2019.